• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

LY-2584702 free base

CAS No. 1082949-67-4

LY-2584702 free base ( —— )

产品货号. M23290 CAS No. 1082949-67-4

LY2584702 是一种选择性 ATP 竞争性 p70S6K 抑制剂 (IC50: 4 nM)。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥437 有现货
5MG ¥940 有现货
10MG ¥1215 有现货
25MG ¥2689 有现货
50MG ¥3629 有现货
100MG ¥5330 有现货
500MG ¥11178 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    LY-2584702 free base
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    LY2584702 是一种选择性 ATP 竞争性 p70S6K 抑制剂 (IC50: 4 nM)。
  • 产品描述
    LY2584702 is a selective, ATP-competitive p70S6K inhibitor(IC50: 4 nM).
  • 体外实验
    LY-2584702 (LY2584702) inhibits phosphorylation of the S6 ribosomal protein (pS6) in HCT116 colon cancer cells with an IC50 of 0.1-0.24 μM. For pS6 inhibition in cells, the IC50=100 nM. LY-2584702 has some activity against the S6K-related kinases MSK2 and RSK at high concentrations (enzyme assay IC50=58-176 nM). LY-2584702 inhibits S6K activity in EOMA cells, as determined by the phosphorylation of its downstream effector S6, in a dose-dependent manner. Proliferation of A549 is significantly inhibited by LY-2584702 (LY2584702) treating over 24 h at 0.1 μM (P<0.05); and the trend of decline is more conspicuous with longer treatment and/or with the increased drug concentration (all P<0.05). Similar results are also observed in SK-MES-1, although the obvious inhibition is led by LY-2584702 at 0.6 μM (P<0.05), much higher than that of A549.
  • 体内实验
    LY-2584702 demonstrates significant single-agent efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models at two dose levels of 2.5 mg/kg twice daily (BID) and 12.5 mg/kg BID. LY-2584702 demonstrates statistically significant tumour growth reduction at TMED50 (threshold minimum effective dose 50%) (2.3 mg/kg) and TMED90 (10 mg/kg) in the HCT116 colon carcinoma xenograft model. To examine the role of S6K in vivo, EOMA cells expressing shAkt3 are implanted in nu/nu mice, then treated for 14 days with LY-2584702 or Rapamycin. Analysis of tumors removed after 14 days shows that LY-2584702 inhibits S6 phosphorylation almost as effectively as Rapamycin. Loss of Akt3 increases tumor growth as compared with pLKO. LY-2584702 treatment alone does not significantly affect the growth of pLKO tumors. However, LY-2584702 significantly reduces the growth of tumors with shAkt3.
  • 同义词
    ——
  • 通路
    PI3K/Akt/mTOR signaling
  • 靶点
    mTOR
  • 受体
    mTOR (p70S6K)
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    1082949-67-4
  • 分子量
    445.42
  • 分子式
    C21H19F4N7
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO:10 mM,warmed with 50oC water bath
  • SMILES
    CN1C=C(N=C1C2CCN(CC2)C3=NC=NC4=C3C=NN4)C5=CC(=C(C=C5)F)C(F)(F)F
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Hollebecque A, Houédé N, Cohen EE, Massard C, Italiano A, Westwood P, Bumgardner W, Miller J, Brail LH, Benhadji KA, Soria JC. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer. 2014 Mar;50(5):876-84. doi: 10.1016/j.ejca.2013.12.006. Epub 2014 Jan 20.
产品手册
关联产品
  • Y16

    Y16 是一种 G 蛋白偶联 Rho GEF 抑制剂;与 Rhosin/G04 协同作用,抑制 LARG-RhoA 相互作用、RhoA 激活和 RhoA 介导的信号传导功能。

  • GPI-1046

    GPI-1046 是亲免素 FKBP12 的非免疫抑制配体。

  • Temsirolimus

    一种雷帕霉素酯和 mTOR 抑制剂,生化 IC50 为 1.74 uM。